GMDA News and Press, Gamida Cell Ltd. From 04/07/22

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, announced that company management will present at the upcoming 21 st Annual Needham Virtual Healthcare Conferenc...

Gamida Cell Ltd. (GMDA) Q4 2021 Earnings Conference Call March 15, 2022 08:00 ET CompanyParticipants Heather DiVecchia - Chief of Staff Julian Adams - Chief Executive Officer Ronit Simantov - Chief Medical Officer & Chief Scientific Officer Michele Korfin - Chief Operating Officer & C...

Image source: The Motley Fool. Gamida Cell Ltd. (NASDAQ: GMDA) Q4 2021 Earnings Call Mar 15, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Gamida Cell Ltd. (GMDA) Q4 2021 Earnings Call Transcript

Gamida Cell press release (NASDAQ:GMDA): FY GAAP EPS of -$1.52 misses by $0.10.  As of December 31, 2021, the company had total cash and cash equivalents of $95.9M. Shares -4.19% PM. For further details see: Gamida Cell GAAP EPS of -$1.52 misses by $0.10

- Initiated rolling BLA submission for omidubicel in the first quarter of 2022 with full BLA submission on track for first half of 2022 - - Finished fourth quarter of 2021 with approximately $96 million in cash; sufficient cash to fund the company’s operations into mid-...

ANIP, ATNX, BBI, OTCQX:CCHWF, CTRN, DOLE, DTIL, GMDA, KMDA, KNDI, KPLT, NRP, OTCPK:RWEOY, SYRS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that company management will present its corporate highlights at the upcoming Oppenheimer 32 nd Annual Healthcare Conference on March 16...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, March 15, 2022, at 8:00 a.m. ET to review its fourth quarter...

Shares of Gamida Cell (GMDA +22.3%) have surged higher after the company today said it started a rolling submission of a Biologics License Application ("BLA") for omidubicel, a treatment for patients with blood cancers in need of stem cell transplant. The company is aiming to complete the sub...

Gamida Cell (NASDAQ:GMDA) began a rolling submission of its biologics license application (BLA) with the U.S. Food and Drug Administration for omidubicel, a treatment for patients with blood cancers in need of stem cell transplant.The company said it remains on track to complete the...